Clinical Trials Browser

Phase 1/2 × Carcinoma × Bevacizumab × Clear all

NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases